Australia · Delayed Price · Currency is AUD Optiscan Imaging Earnings Call Transcripts
Fiscal Year 2025
-
A major transformation is underway, shifting from OEM to private label with a robust pipeline of clinical and veterinary devices. Key partnerships, strong financial backing, and a focus on regulatory milestones position the company for U.S. and global commercialization, with launches targeted for 2026–2027.
-
A strategic shift to private label and diversified offerings has driven expansion into medical, veterinary, and life sciences markets, supported by key global partnerships. Multiple new devices are in production or nearing regulatory submission, with strong financials and projected revenue growth from new product launches.
Fiscal Year 2024
-
A patented real-time imaging platform is advancing through clinical and regulatory milestones, targeting human and veterinary markets with hardware, software, and AI solutions. Strategic partnerships and global expansion support a strong financial position and growth outlook.